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On the background of population ageing atrial fibrillation (AF) has reached epidemic
dimensions in developed countries. This condition is associated with major cardiovascular
morbidity and mortality mainly due to its thrombo-embolic and heart failure related
complications. Left atrial (LA) catheter ablation has emerged as a suitable alternative to
antiarrhythmic drugs for sinus rhythm maintenance at least for paroxysmal atrial
fibrillation in the settings of no/mild LA dilatation. Chronic oral anticoagulation (OAC)
is helpful to prevent AF thromboembolic complications in high-risk patients. OAC is also
protective around ablation procedures in patients with or without an indication for long-
term OAC therapy, emphasizing a slight increase in periprocedural risk of stroke. Due to
the potential catastrophic hemorrhagic complications during trans-septal LA instrumen-
tation, traditional approach on LA ablations involved warfarin discontinuation with
periprocedural heparin bridging. Recent observational data suggests that radiofrequency
(RF) catheter ablation of AF under therapeutic OAC (mainly vitamin K antagonists [VKA])
may reduce the periprocedural risk of complications, mainly thromboembolic events
(possibly including silent strokes). Uninterrupted OAC has been acknowledged as an
alternative to heparin bridging by the recently published consensus and guidelines update
on AF ablation. Currently the recommended therapeutic level of OAC during ablation is low
(such as an INR of 2–2.5). In the general AF settings new OAC (NOAC) have shown non-
inferiority compared to VKA for stroke prevention, with better safety. Rapidly acting NOAC
seems a tempting alternative to VKA at least for the patients taken off OAC before the
ablation, possibly avoiding any post-procedural heparin bridging. However, limited experi-
ence with periprocedural use of NOAC (mainly dabigatran) suggests an increased risk of
bleeding or thromboembolic complications compared with VKA.
& 2012 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
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Atrial fibrillation (AF) is the most common arrhythmia, reach-
ing epidemic dimensions in the developed world due to
population ageing, with an overall prevalence of approximately
1.5–2% [1–3]. The arrhythmia is associated with a significant
increase in mortality, morbidity and hospitalization mainly due
its thromboembolic complications and uncontrolled ventricular
rate, with a five-fold risk of stroke and a three-fold incidence of
congestive heart failure [4]. The two principal targets of therapy
are the prevention of stroke and the alleviation of symptoms
through rhythm or rate control. To accomplish the former,
most patients with AF will require an oral anticoagulant (OAC).
Left atrial (LA) catheter ablation has emerged as a rhythm-
control alternative to antiarrhythmic drugs (AAD). Catheter
ablation procedures are indicated for patients with medically
refractory/recurrent, symptomatic AF. Recent consensus and
guideline update assigned it a class IA indication for first-line
treatment in selected patients with paroxysmal AF and no/
minimal structural heart disease [5–7]. These procedures
comprise ablation in the systemic circulation, often with
conversion from AF to sinus rhythm and are associated with
a significant risk of thromboembolism. Strategies have been
developed to reduce the risk of intra-procedural stroke, like
real-time detection of the newly formed thrombi (transeso-
phageal or intracardiac echocardiography) or thrombus pre-
vention (irrigated tip catheters, aggressive anticoagulation).
However, under the settings of heavy anticoagulation, inad-
vertent transseptal puncture, pericardial effusions as well as
LA perforations are potentially catastrophic complications.2. Thromboembolic risk during atrial
fibrillation ablation
During LA catheterization, catheter manipulation can result in
dislodgement of the previously formed thrombus. Pre-ablation
transesophageal echocardiography can detect LA/LAA defini-
tive thrombi as well as pre-thrombosis states (sludge) [8] and
prevent this type of embolism, many centers performing it
routinely prior to ablation. However the risk seems significant
and warrants this pre-procedural screening only in patients
with non-paroxysmal AF aswell as in patients with paroxysmal
AF and high or intermediate CHADS2 score (4/¼1), especially ifthey are in AF at the time of procedure [9,10]. Predictors of
sludge/thrombus are CHADS2 score4/¼1, dilated LA (445mm
transverse diameter?) and/or depressed LA function (reduced
LAA empting velocities) and previous CHF/ LV dysfunction
(LVEFo35%) [9,10]. The occurrence of a clot/sludge in low risk
patients (CHADS2 0) is rare (o1%), indicating a relative safety of
atrial fibrillation ablation in this subset of patients [10]. The role
of spontaneous echo-contrast is less clear. Although its inci-
dence parallels CHADS2 score it still can be found in approxi-
mately one quarter of low risk patients (CHADS2¼0 and normal
LVEF) [10]. During radiofrequency (RF) ablation embolism to the
cerebral circulation or less commonly to the limbs or other
organs may be produced by charing (hard coagulum produced
by tissue heating, denaturation, and aggregation on the tissue
or catheter surface) and/or thrombus formation [11]. The risk of
stroke due to charing and/or thrombus formation is also higher
in patients with previous cerebrovascular events or higher than
2 CHADS2 score [12]. Overall the risk of a thromboembolic
complication during atrial fibrillation ablation ranges from 0.5
to 5.0% with stroke occurrence of 0.23% and transient ischemic
attack (TIA) of 0.71% [11–13]. Cerebral emboli result usually in
transient neurological deficits (which resolve typically in less
than 1 month) and less commonly produce permanent neuro-
logical sequels [13]. However, silent periprocedural cerebral
thromboembolism detected on MRI seems to be much more
common (more than 14%!), especially when activated clotting
time (ACT) is lower than 250 s and/or when electrical/pharma-
cological cardioversion is performed during procedure [14].
Silent cerebral embolism is also significantly more frequent
during non-irrigated tip RF ablations then during open-irrigated
tip RF ablations or during cryoballoon ablations [15,16]. High
flow perfusion with heparinized saline of the transseptal
sheaths [17] as well as their withdrawal in the right atrium
during ablation (a very popular approach into the electrophy-
siologists community) might reduce the risk of thrombus
formation and therefore the risk of cerebral embolism,
although the latter was never investigated.3. Hemorrhagic risk during atrial fibrillation
ablation
In order to minimize the embolic risk and in accordance with
current guidelines anticoagulants or antiplatelet agents are
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procedure, with the cost increased bleeding risk. Hemorrha-
gic complications are actually the most common complica-
tion of atrial fibrillation ablation, which overall occur in 2–3%
of the procedures [13,18]. More frequent (1–2% of patients)
bleeding occurs at the venous and/or arterial access sites
[13,18,19]. Bleeding severity ranges from a simple hematoma
that can be treated conservatively to complications that may
require vascular repair like pseudoaneurysm or arterovenous
fistula formation. Massive, life-threatening bleedings like
retroperitoneal or rectus sheath hemorrhages might evolve
discretely (like unexplained drop in hemoglobin level) or with
signs of acute severe anemia, but fortunately they are rarely
seen [19].
A not so rare and serious hemorrhagic potentially life-
threatening complication is cardiac tamponade due to car-
diac perforation, which has an overall incidence of 0.5 to
more than 1.3% [13,18], with 1 out of 30 cases being fatal [20].
Cardiac tamponade seems more frequent during ablations in
non-paroxysmal AF (which usually are more extensive) and
in early-experience and/or low-volume centers [21]. Usually
pericardiocentesis, reversal of anticoagulation, and holding
oral anticoagulation for a week manage conservatively this
complication. However open-heart surgical repair may be
required if more than 500–1000 ml blood is drained, or if
drainage continues over 2 h [19]. Recent research suggests
that acute and transitory pericardial effusion without cardiac
tamponade occurs quite commonly (up to 22%!), significantly
more frequent in patients with persistent atrial fibrillation
versus other types (35% vs. 10%) [22].4. Standard anticoagulation strategies to
minimize ablation risks
Ideally, periablation anticoagulation should minimize/elim-
inate the risk of thromboembolic events without significant
increase in bleeding complications. Currently there are sev-
eral possible strategies to accomplish this target, all of them
involving intraprocedural heparin.4.1. Intraprocedural heparin
Optimal anticoagulation with heparin to maintain therapeu-
tic levels during the ablation is important. Thrombi can form
on the transseptal sheath and/or catheters almost immedi-
ately after crossing the septum [11], therefore unfractionated
heparin (UH, a loading dose of 100–150 U/kg followed by
standard infusion) is usually administered prior to or imme-
diately following transseptal puncture during AF ablation
procedures and adjusted to achieve and maintain the recom-
mended activated clotting time (ACT) of more than 300–350 s
[6], especially in patients with spontaneous echo contrast or
significant atrial enlargement. The recommended frequency
with which ACT levels should be monitored is 10–15-minute
intervals until therapeutic anticoagulation is achieved and
then at 15–30-minute intervals for the duration of the
procedure.4.2. The bridging strategy
Standard periablation strategy still largely used and supported
by the current guidelines is pre-procedural discontinuation of
VKA for 3–5 days and intraprocedural intravenous UH, with
pre- and postprocedural ‘bridging’ with intravenous UH or
subcutaneous low molecular weight heparin (LMWH) till effec-
tive post-procedural OAC is resumed [5–7]. LMWH (e.g. enox-
aparin 1mg/kg b.i.d., or dalteparin 200 IU/kg once daily) is
initiated 2 days ahead of procedure with none given in the
morning of the procedure, and postprocedural resumption in
the same evening after access sheath removal or next morning.
Unfortunately, this approach was associated with a high rate of
bleeding complications, especially at vascular access site
[23–25]. Most centers switched to half-dose LMWH and saw less
bleeding, without a higher risk of stroke [26]. Post procedure,
warfarin is restarted the night of the procedure, often using a
double dose for the first 2 days and titrated to an INR of 2–3.5. Alternative strategy to minimize ablation
risk: continuos OAC
The paradigm that for patients undergoing invasive proce-
dures normal coagulation properties are mandatory has been
challenged recently. It has been demonstrated that several
cardiac procedures, including device implantation [27,28],
coronary interventions [29], or even CABG surgery [30] can
be performed safely with continuous OAC (cOAC).
5.1. Vitamin K antagonists
Several studies demonstrated that at least in experienced
centers left atrial ablation is safe when performed in patients
taking therapeutic VKA. This strategy offers the advantage of
greater simplicity for both patients and physicians with
possibly a lower risk of bleeding compared with LWMH.
VKA therapy is continued the whole periablation period at a
low therapeutic INR (ideally 2.0–2.5, preferably with INRs
drawn weekly). The comparison of continuous therapeutic
VKA (INR 2–3.5) with full-dose and respectively half-dose
LMWH bridging in 355 patients undergoing LA catheter
ablation for persistent AF showed that cOAC vs. LMWH-
bridging is at least as effective in stroke prevention and
superior in terms of minor or major bleeding complications
(actually there was only 1 patient with pericardial effusion
but without tamponade in the cOAC group) [26]. The same
group reported latter in larger cohort of 3027 consecutive
patients with LA ablation for AF that continuous VKA (with
INR 41.8) has a lower incidence of hemorrhagic complica-
tions (1.1%), pericardial effusion (0.29%), cardiac tamponade
(0.16%) and fewer ischemic strokes (0.098%) [31] versus tradi-
tional bridging strategy [32]. We noticed that in our center in
the last 2 years since we started to perform AF ablations on
cOAC, the cognitive score of patients the day after ablation is
significantly higher by comparison with patients with brid-
ging therapy (unpublished observations Dr. Vatasescu), pos-
sibly related to reduction/elimination of silent cerebral
embolism. Two recent single center data showed conflicting
data on periprocedural silent embolism as detected by MRI,
with one suggesting that silent embolism is not reduced
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other showing a 50% reduction (i.e. incidence o7%) [34].
However, both studies found non-paroxysmal AF, complex
and prolonged ablations and dilated LA as predictors of silent
cerebral embolism [33,34].
Continuous OAC seem to add benefit versus bridging
therapy even on top of open-tip heparinized-saline irrigated
catheters. In a large study on 6454 patients [35], 2488 under-
went ablation with an 8-mm ablation catheter and pre-
procedural VKA discontinuation (group 1), 1348 underwent
ablation with an open irrigated catheter and pre-procedural
VKA discontinuation (group 2), and 2618 underwent ablation
with an open irrigated catheter with cOAC (group 3). Ablation
with a therapeutic INR (2.0–2.5) resulted in a reduction of
periprocedural thromboembolic events [odds ratio (OR) 0.54;
95% confidence interval (CI) 0.32–0.89; P 1/4 0.017] compared
to the traditional bridging approach. Major bleeding compli-
cations (i.e. bleeding requiring transfusions, hemopericar-
dium, hemothorax, and retroperitoneal bleeding) and
pericardial effusion in patients on cOAC were also lower
(0.8% vs. 1.1% in patients with bridging) as well as emergent
surgical exploration. Moreover, if pericardial tamponade
occurs in the presence of therapeutic OAC, it can be managed
conservatively by percutaneous drainage in all patients and it
seems not to be more severe than in patients with bridging
therapy [36]. In the case of persistent bleeding or cardiac
tamponade warfarin reversal is possible with fresh frozen
plasma, prothrombin complex concentrates (PCC: Factors II,
VII, IX, and X) or recombinant activated factor VII (rFVIIa) [37].
Another advantage of AF ablation on VKA treatment is that at
therapeutic INR VKA do not affect clinical significance of ACT,
patients on cOAC usually have a more stable therapeutic ACT
(4300–350 s), after a standard intravenous bolus of UH and
necessitate smaller amounts of intraprocedural UH [38].
These favorable results can be criticized due to the fact that
studies were done in large volume experienced centers and
assisted by intracardiac echocardiography, which add extra-
safety but is not always available and has significant extra-
costs. Recent data from medium volume centers proved that
transseptal puncture and LA ablation can be safely done
without intracardiac echocardiography guidance [39–41].
Furthermore, some researchers advocate that the frequent
and uncomfortable ACT dozing during AF ablation might not
be necessary at all in patients with therapeutic INR at the time
of the procedure after the initial standard bolus of UH [41].
Finally, analysis of pooled data from published studies
comparing cOAC (6400 patients) with heparin-bridging
(21,000 patients) during AF catheter ablation confirmed that
uninterrupted VKA treatment reduces the risk of throm-
boembolic complications without increasing the risk of
bleeding [42].
The consistence of data supporting cOAC during AF abla-
tion is acknowledged by the most recent practice consensus
and guidelines [5–7] and is reflected in significant change in
practice across the European centers [43,44].
5.2. Novel oral anticoagulants
Recently new OAC (NOAC) like dabigatran (DG) or rivaroxaban
(RX) proved superior efficacy and safety by comparison withwarfarin in stroke prevention in patients with non-valvular
AF [45,46]. Moreover, patients treated with DG seem to have
similar rates of bleeding and stroke during invasive proce-
dures (as pacemaker/defibrillator insertion, dental proce-
dures, diagnostic procedures, cataract removal, colonoscopy,
and joint replacement) versus patients on VKA [47]. However
management of periprocedural anticoagulation during AF
ablation in patients on DG is currently not clear. A recent
study in 8 high-volume centers found a higher incidence of
bleeding and pericardial effusions and no benefit in throm-
boembolism prevention in patients treated with DG com-
pared with warfarin [48]. Although these results are contra
intuitive in the light of previous data in the general AF
settings [45], there are several possible explanations. DG
was stopped only in the morning of the procedure and was
restarted 3 h after the procedure, which is nearly equivalent
to uninterrupted DG. Due to its half-life of 14–17 h, manu-
facturer’s recommendations are to stop it at least 1 day before
invasive procedures in patients with normal renal function
(or even longer when complete hemostasis is required).
Another possible explanation is the well known unpredict-
able interaction of DG with ACT [49,50], which makes ACT
unstable during procedure and quantity of necessary UH
difficult to estimate [51]. A safer anticoagulation approach
would be to use smaller DG doses or to hold the DG for 1–2
days before the ablation and resume it the following morn-
ing. In one study of 211 consecutive patients who underwent
AF ablation, of whom 110 received 110 mg DG twice daily
(stopped in the morning of procedure and resumed next day),
there was no difference in embolic rate (including silent
stroke on MRI) and less bleedings by comparison with 111
patients on therapeutic continuous warfarin (INR 2–3) [52]. A
recent nonrandomized study in 34 patients with periproce-
dural NOAC discontinued DG for 36 h before the procedure
and restarted it 22 h after the procedure, bridging with half-
dose LMWH after the procedure [53]. There were no pre-
procedural or intraprocedural thromboembolic episodes or
bleeding. Other options include using newer oral anticoagu-
lants other than DG, such as RX [46], which has a shorter
half-life and might be reversible with PCC if bleeding or
tamponade were to occur [54].
5.3. Infrequent strategies: antiplatelets alone
Very limited data suggests that if pre-ablation TEE can rule
out LA/LAA clot/sludge, aspirin alone can be used to prevent
periprocedural thromboembolism either pre-ablation [55] or
even after ablation [56] in relatively low risk patients (i.e.
paroxysmal atrial fibrillation and CHADS2 score of o/¼1).
Probably this type of strategy might be strictly limited to
young patients with CHADS2 0, no structural heart disease
and relatively limited LA lesions during ablation.6. Conclusions
Ablation for atrial fibrillation is a pertinent and possibly a
lasting treatment alternative to antiarrhythmic drugs for
prevention of recurrences in symptomatic patients. Bleeding
and embolism remained a significant risk in standard
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convincing data that clearly demonstrates the efficacy and
safety of LA catheter ablation on continuous VKA. Continua-
tion of therapeutic warfarin during ablation of AF may be the
best strategy, especially in patients with nonparoxysmal AF,
patients with higher thromboembolic risk scores, and
patients who require extensive LA ablation. The role of new
oral anticoagulants as replacements for warfarin in AF abla-
tion protocols is the subject of ongoing research.
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